Back
Kahn Swick & Foti reminds GeneDx investors of Aug. 3, 2026 lead plaintiff deadline

Kahn Swick & Foti reminds GeneDx investors of Aug. 3, 2026 lead plaintiff deadline

The proposed Connecticut securities class action alleges GeneDx failed to disclose margin pressure, revenue misses, reduced guidance and a Fabric Genomics impairment before shares fell 49.2% on May 4, 2026.

Fact Check
The GlobeNewswire Kahn Swick & Foti release directly confirms every element of the claim: the KSF reminder, the Aug. 3, 2026 lead plaintiff deadline, allegations of undisclosed margin pressure, missed revenue expectations, and Fabric Genomics impairment, and the 49.2% share decline on May 4, 2026. GeneDx's own IR release confirms the underlying facts (guidance cut to $475-490M, 69% adjusted gross margin, Fabric Genomics impairment). Multiple independent law firm releases (Hagens Berman, Robbins LLP, Levi & Korsinsky) corroborate the 49.2% drop ($33.42/share) and the $31.2M impairment. Sources are consistent with no meaningful conflict.
Summary

Kahn Swick & Foti said investors who purchased or otherwise acquired GeneDx Holdings Corp. shares between April 16, 2025 and May 4, 2026 have until Aug. 3, 2026 to seek appointment as lead plaintiff in a proposed securities class action pending in the United States District Court for the District of Connecticut. The case, Basma v. GeneDx Holdings Corp., alleges GeneDx and certain executives failed to disclose material information in violation of federal securities laws. According to the complaint, GeneDx disclosed on May 4, 2026 that adjusted gross margin fell to 69% from 74%, it missed revenue estimates for both its exome and genome lines, it cut full-year revenue guidance to $475 million to $490 million from $540 million to $550 million, and it recorded a $31.2 million impairment loss tied to Fabric Genomics. KSF said GeneDx shares fell $33.42, or 49.2%, on that news.

Terms & Concepts
  • lead plaintiff: An investor appointed by the court to represent the proposed class and help oversee the litigation.
  • adjusted gross margin: A profitability measure showing revenue left after direct costs, excluding certain items defined by the company.
  • impairment loss: An accounting charge taken when an asset or acquisition is judged to be worth less than its recorded value.